Teva Pharmaceuticals USA Inc. v. AstraZeneca Pharmaceuticals LP
1:15-cv-00050
Overview
Parties
Movant
AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)
Represented By
0 Attorneys ListedDefendant
Teva Pharmaceuticals USA Inc. Operating Company
Represented By
0 Attorneys ListedCounter Defendant
Amylin Pharmaceuticals LLC Operating Company
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Sanofi-Aventis U.S. LLC et al. v. Amylin Pharmaceuticals, LLC et al.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7297761
Pharmaceutical compositions containing exendins
|
Filed: 2004-07-19
Issued: 2007-11-20
|
Expired (Term Ended)
Expires: 2017-10-15
|
|
|
US7741269
Exendins and exendin agonists for weight reduction and obesity
|
Filed: 2004-07-20
Issued: 2010-06-22
|
Expired (Term Ended)
Expires: 2018-07-05
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).